IBDEI0DF ; ; 09-MAY-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 09, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18134,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,18135,0)
 ;;=203.01^^110^1109^103
 ;;^UTILITY(U,$J,358.3,18135,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18135,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,18135,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,18135,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,18136,0)
 ;;=238.6^^110^1109^106
 ;;^UTILITY(U,$J,358.3,18136,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18136,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,18136,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,18136,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,18137,0)
 ;;=205.00^^110^1109^4
 ;;^UTILITY(U,$J,358.3,18137,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18137,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,18137,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,18137,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,18138,0)
 ;;=205.01^^110^1109^6
 ;;^UTILITY(U,$J,358.3,18138,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18138,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,18138,1,5,0)
 ;;=5^AML, In Remission
 ;;^UTILITY(U,$J,358.3,18138,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,18139,0)
 ;;=205.10^^110^1109^49
 ;;^UTILITY(U,$J,358.3,18139,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18139,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,18139,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,18139,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,18140,0)
 ;;=205.11^^110^1109^51
 ;;^UTILITY(U,$J,358.3,18140,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18140,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,18140,1,5,0)
 ;;=5^CML, In Remission
 ;;^UTILITY(U,$J,358.3,18140,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,18141,0)
 ;;=289.0^^110^1109^53
 ;;^UTILITY(U,$J,358.3,18141,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18141,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,18141,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,18141,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,18142,0)
 ;;=238.4^^110^1109^107
 ;;^UTILITY(U,$J,358.3,18142,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18142,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,18142,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,18142,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,18143,0)
 ;;=V58.61^^110^1109^123
 ;;^UTILITY(U,$J,358.3,18143,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18143,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,18143,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,18143,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,18144,0)
 ;;=282.49^^110^1109^115
 ;;^UTILITY(U,$J,358.3,18144,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18144,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,18144,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,18144,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,18145,0)
 ;;=289.89^^110^1109^14
 ;;^UTILITY(U,$J,358.3,18145,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18145,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,18145,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,18145,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,18146,0)
 ;;=238.79^^110^1109^86
 ;;^UTILITY(U,$J,358.3,18146,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18146,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,18146,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis NEC
 ;;^UTILITY(U,$J,358.3,18146,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,18147,0)
 ;;=287.30^^110^1109^108
 ;;^UTILITY(U,$J,358.3,18147,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18147,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,18147,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,18147,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,18148,0)
 ;;=288.09^^110^1109^7
 ;;^UTILITY(U,$J,358.3,18148,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18148,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,18148,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,18148,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,18149,0)
 ;;=284.81^^110^1109^13
 ;;^UTILITY(U,$J,358.3,18149,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18149,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,18149,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,18149,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,18150,0)
 ;;=284.89^^110^1109^12
 ;;^UTILITY(U,$J,358.3,18150,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18150,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,18150,1,5,0)
 ;;=5^Aplastic Anemia d/t Chr disease
 ;;^UTILITY(U,$J,358.3,18150,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,18151,0)
 ;;=289.84^^110^1109^116
 ;;^UTILITY(U,$J,358.3,18151,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18151,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,18151,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,18151,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,18152,0)
 ;;=204.02^^110^1109^2
 ;;^UTILITY(U,$J,358.3,18152,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18152,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,18152,1,5,0)
 ;;=5^ALL, In Relapse
 ;;^UTILITY(U,$J,358.3,18152,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,18153,0)
 ;;=204.12^^110^1109^48
 ;;^UTILITY(U,$J,358.3,18153,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18153,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,18153,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,18153,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,18154,0)
 ;;=204.21^^110^1109^113
 ;;^UTILITY(U,$J,358.3,18154,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18154,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,18154,1,5,0)
 ;;=5^Subacute LL in Remission
 ;;^UTILITY(U,$J,358.3,18154,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,18155,0)
 ;;=204.20^^110^1109^114
 ;;^UTILITY(U,$J,358.3,18155,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18155,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,18155,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,18155,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,18156,0)
 ;;=204.22^^110^1109^112
 ;;^UTILITY(U,$J,358.3,18156,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18156,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,18156,1,5,0)
 ;;=5^Subacute LL in Relapse
 ;;^UTILITY(U,$J,358.3,18156,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,18157,0)
 ;;=203.02^^110^1109^102
 ;;^UTILITY(U,$J,358.3,18157,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18157,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,18157,1,5,0)
 ;;=5^Multiple Myeloma In Relapse
 ;;^UTILITY(U,$J,358.3,18157,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,18158,0)
 ;;=205.02^^110^1109^5
 ;;^UTILITY(U,$J,358.3,18158,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18158,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,18158,1,5,0)
 ;;=5^AML, In Relapse
 ;;^UTILITY(U,$J,358.3,18158,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,18159,0)
 ;;=205.12^^110^1109^50
 ;;^UTILITY(U,$J,358.3,18159,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18159,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,18159,1,5,0)
 ;;=5^CML, In Relapse
 ;;^UTILITY(U,$J,358.3,18159,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,18160,0)
 ;;=V10.91^^110^1109^63
 ;;^UTILITY(U,$J,358.3,18160,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18160,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,18160,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,18160,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,18161,0)
 ;;=V10.91^^110^1109^73
 ;;^UTILITY(U,$J,358.3,18161,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18161,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,18161,1,5,0)
 ;;=5^H/O Unspecified Malignant Neoplasm
 ;;^UTILITY(U,$J,358.3,18161,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,18162,0)
 ;;=465.9^^110^1110^72
 ;;^UTILITY(U,$J,358.3,18162,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18162,1,4,0)
 ;;=4^465.9
 ;;^UTILITY(U,$J,358.3,18162,1,5,0)
 ;;=5^URI
 ;;^UTILITY(U,$J,358.3,18162,2)
 ;;=URI^269878
 ;;^UTILITY(U,$J,358.3,18163,0)
 ;;=462.^^110^1110^63
 ;;^UTILITY(U,$J,358.3,18163,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18163,1,4,0)
 ;;=4^462.
 ;;^UTILITY(U,$J,358.3,18163,1,5,0)
 ;;=5^Sore Throat
 ;;^UTILITY(U,$J,358.3,18163,2)
 ;;=^2653
 ;;^UTILITY(U,$J,358.3,18164,0)
 ;;=466.0^^110^1110^2
 ;;^UTILITY(U,$J,358.3,18164,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18164,1,4,0)
 ;;=4^466.0
 ;;^UTILITY(U,$J,358.3,18164,1,5,0)
 ;;=5^Bronchitis,Acute
 ;;^UTILITY(U,$J,358.3,18164,2)
 ;;=^259084
 ;;^UTILITY(U,$J,358.3,18165,0)
 ;;=112.1^^110^1110^81
 ;;^UTILITY(U,$J,358.3,18165,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18165,1,4,0)
 ;;=4^112.1
 ;;^UTILITY(U,$J,358.3,18165,1,5,0)
 ;;=5^Vulvovaginitis,Candidal
 ;;^UTILITY(U,$J,358.3,18165,2)
 ;;=^18615
 ;;^UTILITY(U,$J,358.3,18166,0)
 ;;=616.0^^110^1110^12
 ;;^UTILITY(U,$J,358.3,18166,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18166,1,4,0)
 ;;=4^616.0
 ;;^UTILITY(U,$J,358.3,18166,1,5,0)
 ;;=5^Cervicitis
 ;;^UTILITY(U,$J,358.3,18166,2)
 ;;=^21925
 ;;^UTILITY(U,$J,358.3,18167,0)
 ;;=599.0^^110^1110^73
 ;;^UTILITY(U,$J,358.3,18167,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18167,1,4,0)
 ;;=4^599.0
 ;;^UTILITY(U,$J,358.3,18167,1,5,0)
 ;;=5^UTI
 ;;^UTILITY(U,$J,358.3,18167,2)
 ;;=UTI^124436
 ;;^UTILITY(U,$J,358.3,18168,0)
 ;;=460.^^110^1110^48
 ;;^UTILITY(U,$J,358.3,18168,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18168,1,4,0)
 ;;=4^460.
 ;;^UTILITY(U,$J,358.3,18168,1,5,0)
 ;;=5^Nasopharyngitis, Acute
 ;;^UTILITY(U,$J,358.3,18168,2)
 ;;=^26543
 ;;^UTILITY(U,$J,358.3,18169,0)
 ;;=372.30^^110^1110^13
 ;;^UTILITY(U,$J,358.3,18169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18169,1,4,0)
 ;;=4^372.30
 ;;^UTILITY(U,$J,358.3,18169,1,5,0)
 ;;=5^Conjunctivitis
 ;;^UTILITY(U,$J,358.3,18169,2)
 ;;=^27546
 ;;^UTILITY(U,$J,358.3,18170,0)
 ;;=595.9^^110^1110^14
 ;;^UTILITY(U,$J,358.3,18170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18170,1,4,0)
 ;;=4^595.9
 ;;^UTILITY(U,$J,358.3,18170,1,5,0)
 ;;=5^Cystitis
 ;;^UTILITY(U,$J,358.3,18170,2)
 ;;=^30304
 ;;^UTILITY(U,$J,358.3,18171,0)
 ;;=110.1^^110^1110^15
 ;;^UTILITY(U,$J,358.3,18171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18171,1,4,0)
 ;;=4^110.1
 ;;^UTILITY(U,$J,358.3,18171,1,5,0)
 ;;=5^Dermatophytosis Nail
 ;;^UTILITY(U,$J,358.3,18171,2)
 ;;=^33173
 ;;^UTILITY(U,$J,358.3,18172,0)
 ;;=562.11^^110^1110^16
